John Donovan, MD
President & CEO
John Donovan is an anesthesiologist with over 20 years of experience in clinical medicine with a focus on postsurgical pain management. Dr. Donovan has also held a number of senior business development positions for development stage anesthesia/pain biotechs, including Signature Therapeutics and Anesiva (NASDAQ: ANSV).
Previously, Dr. Donovan played a leading role architecting and implementing the strategic growth of Alta Bates Summit Medical Center Anesthesiology Group having served as department chair and medical group president. Dr. Donovan has conducted research and published on postsurgical pain, including the use of continuous peripheral nerve blocks for TKA, and has also served as an advisor to a variety of emerging life science businesses.
Dr. Donovan completed his residency in anesthesiology at the University of California San Francisco where he was chief resident and continues to maintain an active faculty appointment. He is a founder of Sutter Health Helps Haiti which responded to the 2010 earthquake and continues to support perioperative care and education in Haiti.
Dr. Donovan earned BS and MD degrees from Georgetown University and an MBA from the Haas School of Business at the University of California Berkeley.
Frank J. Bellizzi, DMD
Frank Bellizzi has over 25 years of experience, within and beyond Life Sciences, as an operator, consultant and advisor leading business transformation and growth. Immediately prior to co-founding Concentric, Dr. Bellizzi was CEO of HydraDx, a saliva-based platform for real time health monitoring using a connected device. Dr. Bellizzi also served as President of Zila Pharmaceuticals (NASDAQ: ZILA) where he successfully created and implemented a strategy to build an oral cancer detection business, growing its flagship product, ViziLite® Plus, into the leading oral cancer detection test in the U.S. and internationally.
Dr. Bellizzi is also Managing Director of Indalo Ventures, a specialty advisory and investment firm he founded in 2001 to incubate, launch and scale emerging, high growth businesses. A number of his assignments have included assuming short-term senior operating positions to create and implement turn around and growth strategies for a variety of public and private companies.
In addition, as Chief Financial Officer and Chief Operating Officer of Streampipe, a rich media software company, Dr. Bellizzi engineered all aspects of the company’s growth and successful sale to Loudeye (NASDAQ: LOUD).
Earlier in his career, as a member of Booz, Allen & Hamilton’s Health Industries Practice, Dr. Bellizzi facilitated a number of high-profile engagements, including the merger and integration of two leading West Coast health systems, the acquisition strategy for a leading New York health system, and the operational revitalization of the Australian health care system.
Dr. Bellizzi earned his MBA from the Wharton School of the University of Pennsylvania, his DMD from the University of Pennsylvania School of Dental Medicine, and his BS from Georgetown University.
Craig Husfeld, PhD
Craig Husfeld is a synthetic and medicinal chemist with 15 years of pharmaceutical experience. Dr. Husfeld has successfully overseen the synthetic and medicinal chemistry and early-stage CMC work for multiple development stage biotech companies in the analgesic space, including as Director of Medicinal Chemistry at Elysium Therapeutics where he has focused on creating diversion-resistant opioid drug formulations.
From 2008 to 2014, Dr. Husfeld was Director of Chemistry at Signature Therapeutics (Pharmacofore), where he led the development of abuse-deterrent opioid prodrugs. Prior to his role at Signature, Dr. Husfeld served as a senior researcher at Theravance.
Dr. Husfeld received a BS in chemistry from University of California, Riverside and a PhD in synthetic organic chemistry from Stanford University.